06/02/2023Published by Fondazione Gianni Bonadonna at 06/02/2023Categories Events UncategorizedFederated learning to predicting chemotherapy response in triple-negative breast cancer
30/01/2023Published by Fondazione Gianni Bonadonna at 30/01/2023Categories Events UncategorizedClinical benefits with futibatinib in intra-hepatic cholangiocarcinoma
23/01/2023Published by Fondazione Gianni Bonadonna at 23/01/2023Categories Events UncategorizedPARP inhibitors in advanced prostate cancer, determining HRR genes alterations is crucial for outcomes
16/01/2023Published by Fondazione Gianni Bonadonna at 16/01/2023Categories Events UncategorizedPromising results with lurbinectedin in relapsed Ewing sarcoma
09/01/2023Published by Fondazione Gianni Bonadonna at 09/01/2023Categories Events UncategorizedTrastuzumab deruxtecan in HER2+ metastatic breast cancer
02/01/2023Published by Fondazione Gianni Bonadonna at 02/01/2023Categories Events UncategorizedSurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma
19/12/2022Published by Fondazione Gianni Bonadonna at 19/12/2022Categories Events UncategorizedThe bispecific antibody zanidatamab in HER2 expressing solid tumors
12/12/2022Published by Fondazione Gianni Bonadonna at 12/12/2022Categories Events UncategorizedFondazione Michelangelo at the San Antonio Breast Cancer Symposium
05/12/2022Published by Fondazione Gianni Bonadonna at 05/12/2022Categories Events UncategorizedCombination of olaparib and radiotherapy in triple-negative breast cancer
